Skip to content
Recall Observatory FDA recall evidence

Device product

Penumbra 3D Revascularization Device It is indicated for used in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral-M1 and M2 segments) within 8 hours of symptom onset. Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment.

Z-2702-2017

June 09, 2017

Class I

Product summary

Firm
Penumbra Inc.
Event
Event 77571
Status
Terminated
Classification
Class I
Quantity
155 units
Official record key
device-enforcement:Z-2702-2017

Official wording

Reason: Penumbra has identified an issue in these four lots involving a raw material component of the delivery wire. This issue could result in breakage of the delivery wire, which could potentially lead to serious patient injury or death.

Code information: Lots C00644, C00645, C00646, C00717

Distribution pattern: Nationwide Distribution to the following states: AZ, CA, CO, FL, IN, MA, MI, MN, NV, NY, OH, OK, PA, SC, TN, TX, UT, VA, WV

Derived failure modes

  • Unknown

    reason.no_named_rule · v1.0.0

    Penumbra has identified an issue in these four lots involving a raw material component of the delivery wire. This issue could result in breakage of the delivery wire, which could potentially lead to serious patient injury or death.